An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.

Related articles

04 Feb 2013

Quantitative MR evaluation of atrophy, as well as perfusion and diffusion alterations within hippocampi in patients with Alzheimer’s disease and mild cognitive impairment

Anna Zimny, Joanna Bladowska, [...] Małgorzata Neska, Kamila Petryszyn, Maciej Guziński, Paweł Szewczyk, Jerzy Leszek, Marek Sąsiadek - Show fewer authors

DOI: 10.12659/MSM.883757

31 Aug 2015 : Clinical Research

Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease

Jurgita Kuzmickienė, Gintaras Kaubrys

DOI: 10.12659/MSM.895381

12 Nov 2015 : Clinical Research

Vascular Factors and Cognitive Dysfunction in Alzheimer Disease

Maria Pąchalska, Leszek Bidzan, [...] Mariola Bidzan, Jolanta Góral-Półrola - Show fewer authors

DOI: 10.12659/MSM.894550

21 Nov 2015 : Animal Research

Treatment Efficacy of NGF Nanoparticles Combining Neural Stem Cell Transplantation on Alzheimer’s Disease Model Rats

Yan Chen, Cuihuan Pan, [...] Aiguo Xuan, Liping Xu, Guoqing Bao, Feiei Liu, Jie Fang, Dahong Long - Show fewer authors

DOI: 10.12659/MSM.894567

14 Dec 2015 : Clinical Research

Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease

Jurgita Kuzmickienė, Gintaras Kaubrys

DOI: 10.12659/MSM.896327

23 Apr 2009

Aggressive and impulsive behaviors in Frontotemporal dementia and Alzheimer's disease

Bozena Grochmal-Bach, Leszek Bidzan, [...] Maria Pachalska, Mariola Bidzan, Beata Lukaszewska, Anna Pufal - Show fewer authors